Nkarta, Inc.
NKTXNext catalyst
Fludarabine, Cyclophosphamide
Lupus Nephritis
Get an email about NKTX's next catalysts
Track Nkarta (NKTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 3 past
Fludarabine, Cyclophosphamide Phase 2 Est. Readout
Primary completion for Fludarabine, Cyclophosphamide trial (NCT06557265) in Lupus Nephritis
SourceHow NKTX's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine, Cyclophosphamide | Phase 2 | Lupus Nephritis | - | - |
NKX019 | Phase 2 | Systemic Sclerosis | - | - |
autoimmune diseases
1 drug in this indication
myositis, systemic sclerosis (also ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, primary membranous nephropathy)
1 drug in this indication
idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Nkarta, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Nkarta, Inc.'s (NKTX) pipeline across Phase 2. Its lead program is Fludarabine, Cyclophosphamide (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nkarta, Inc.'s next FDA catalyst?β
Nkarta, Inc.'s (NKTX) next tracked catalyst is a Phase 2 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NKTX biotech catalysts?β
Add NKTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nkarta, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
